B Keymeulen

Summary

Affiliation: Vrije Universiteit Brussel
Country: Belgium

Publications

  1. ncbi New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes
    B Keymeulen
    Academisch Ziekenhuis and Diabetes Research Centre Brussels Free University VUB, Laarbeeklaan 103, B 1090 Brussels, Belgium
    Acta Clin Belg 61:275-85. 2006
  2. ncbi Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
    Bart Keymeulen
    Academic Hospital and Diabetes Research Center, Brussels Free University VUB, Brussels
    N Engl J Med 352:2598-608. 2005
  3. ncbi Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients
    E Vandemeulebroucke
    Diabetes Research Center, Brussels Free University VUB, 1090 Brussels, Belgium
    Diabetologia 53:36-44. 2010
  4. ncbi Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index
    I Weets
    Diabetes Research Center, Free University, Brussels, Belgium
    Diabetologia 44:40-7. 2001
  5. ncbi Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
    B Keymeulen
    Diabetes Research Center and University Hospital, Brussels Free University VUB, Laarbeeklaan 103, 1090 Brussels, Belgium
    Diabetologia 53:614-23. 2010
  6. ncbi Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: impli
    J De Grijse
    Diabetes Research Center, Brussels Free University VUB, Laarbeeklaan 103, B 1090 Brussels, Belgium
    Diabetologia 53:517-24. 2010
  7. ncbi Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives
    I Truyen
    Diabetes Research Center, Brussels Free University VUB, Laarbeeklaan 103, 1090, Brussels, Belgium
    Diabetologia 50:2143-6. 2007
  8. ncbi Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes
    I Truyen
    Diabetes Research Center, Brussels Free University VUB, Brussels, Belgium
    Clin Exp Immunol 149:243-50. 2007
  9. ncbi Restoring a functional beta-cell mass in diabetes
    D Pipeleers
    Diabetes Research Center, Brussels Free University VUB, JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
    Diabetes Obes Metab 10:54-62. 2008
  10. ncbi Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients
    Pieter Gillard
    Department of Diabetology, Diabetes Research Center and University Hospital Brussels, Brussels Free University VUB, Brussels, Belgium
    Transplantation 87:402-7. 2009

Detail Information

Publications31

  1. ncbi New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes
    B Keymeulen
    Academisch Ziekenhuis and Diabetes Research Centre Brussels Free University VUB, Laarbeeklaan 103, B 1090 Brussels, Belgium
    Acta Clin Belg 61:275-85. 2006
    ....
  2. ncbi Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
    Bart Keymeulen
    Academic Hospital and Diabetes Research Center, Brussels Free University VUB, Brussels
    N Engl J Med 352:2598-608. 2005
    ..To provide proof of this therapeutic principle at the metabolic level, we initiated a phase 2 placebo-controlled trial with a humanized antibody, an aglycosylated human IgG1 antibody directed against CD3 (ChAglyCD3)...
  3. ncbi Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients
    E Vandemeulebroucke
    Diabetes Research Center, Brussels Free University VUB, 1090 Brussels, Belgium
    Diabetologia 53:36-44. 2010
    ....
  4. ncbi Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index
    I Weets
    Diabetes Research Center, Free University, Brussels, Belgium
    Diabetologia 44:40-7. 2001
    ....
  5. ncbi Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
    B Keymeulen
    Diabetes Research Center and University Hospital, Brussels Free University VUB, Laarbeeklaan 103, 1090 Brussels, Belgium
    Diabetologia 53:614-23. 2010
    ..The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3...
  6. ncbi Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: impli
    J De Grijse
    Diabetes Research Center, Brussels Free University VUB, Laarbeeklaan 103, B 1090 Brussels, Belgium
    Diabetologia 53:517-24. 2010
    ....
  7. ncbi Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives
    I Truyen
    Diabetes Research Center, Brussels Free University VUB, Laarbeeklaan 103, 1090, Brussels, Belgium
    Diabetologia 50:2143-6. 2007
    ..We investigated whether adiponectin, an insulin sensitiser, can serve as an additional predictive marker for type 1 diabetes in first-degree relatives of known patients...
  8. ncbi Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes
    I Truyen
    Diabetes Research Center, Brussels Free University VUB, Brussels, Belgium
    Clin Exp Immunol 149:243-50. 2007
    ..Together with initially IA-2A-positive relatives these individuals qualify for standardized beta cell function tests in view of prevention trials...
  9. ncbi Restoring a functional beta-cell mass in diabetes
    D Pipeleers
    Diabetes Research Center, Brussels Free University VUB, JDRF Center for Beta Cell Therapy in Diabetes, Brussels, Belgium
    Diabetes Obes Metab 10:54-62. 2008
    ..Comparison of the data with those in non-diabetic controls helps targeting and monitoring of therapeutic interventions...
  10. ncbi Functional beta-cell mass and insulin sensitivity is decreased in insulin-independent pancreas-kidney recipients
    Pieter Gillard
    Department of Diabetology, Diabetes Research Center and University Hospital Brussels, Brussels Free University VUB, Brussels, Belgium
    Transplantation 87:402-7. 2009
    ..To compare functional beta-cell mass and insulin sensitivity in insulin-independent pancreas-kidney recipients with that in age- and body mass index-matched nondiabetic kidney recipients and normal controls...
  11. ncbi Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients
    Robert Hilbrands
    Diabetes Research Center and Universitair Ziekenhuis Brussels, Brussels Free University Vrije Universiteit Brussel VUB, Brussels, Belgium
    Diabetes 58:2267-76. 2009
    ..This retrospective analysis examines whether differences in recipient characteristics at the time of transplantation are correlated with inadequate graft function...
  12. ncbi Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts
    Pieter Gillard
    Academisch Ziekenhuis and Diabetes Research Center, Brussels Free University, Brussels, Belgium
    Transplantation 85:256-63. 2008
    ..Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with SIR-TAC combination therapy...
  13. ncbi Beta-cell transplantation restores metabolic control and quality of life in a patient with subcutaneous insulin resistance
    Pieter Gillard
    Diabetes Research Center and Academic Hosptial, Vrije Universiteit Brussels, Brussels, Belgium
    Diabetes Care 27:2243-4. 2004
  14. ncbi A view on beta cell transplantation in diabetes
    Daniel Pipeleers
    Free University of Brussels VUB, Brussels, Belgium
    Ann N Y Acad Sci 958:69-76. 2002
    ..The future of these grafts will depend on the development of techniques for the neogenesis of beta cells...
  15. ncbi Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes
    K Decochez
    Diabetes Research Center, Brussels Free University VUB, Laarbeeklaan 103, 1090 Brussels, Belgium
    Diabetologia 48:687-94. 2005
    ..We investigated whether specific combinations of immune and genetic markers can identify subgroups with more homogeneous progression to clinical onset...
  16. ncbi Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients
    Babak Movahedi
    Department of Surgery, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
    Transpl Int 16:186-90. 2003
    ..We conclude that this laparoscopic procedure is a feasible, convenient, and safe alternative method of islet transplantation. Moreover, it allows multiple deliveries of islets into the same liver segment...
  17. ncbi Immune responses against islet allografts during tapering of immunosuppression--a pilot study in 5 subjects
    V A L Huurman
    Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Clin Exp Immunol 169:190-8. 2012
    ..Immune monitoring studies may help guiding tapering of immunosuppression after islet cell transplantation, even though we do not have formal prove yet that the observed changes reflect direct effects of immune suppression on immunity...
  18. ncbi The surgical history of the amputated limb according to the indication for revascularization: diabetic foot, acute ischaemia, aneurysmal disease, chronic arterial occlusive disease
    D Aerden
    Department of Vascular Surgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    Acta Chir Belg 111:384-8. 2011
    ..To investigate whether the indication for the first revascularization (diabetic foot, acute ischaemia, aneurysmal disease, chronic occlusive disease) determines the surgical history and survival time in amputated limbs...
  19. ncbi Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients
    Bart Keymeulen
    Academisch Ziekenhuis and Diabetes Research Center, Brussels Free University VUB, Brussels, Belgium
    Blood 115:1145-55. 2010
    ..This phenomenon may also direct new research avenues to understand the still ill-defined nature of stimuli triggering EBV reactivation in vivo...
  20. ncbi A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects
    Katelijn Decochez
    Diabetes Unit, Department of Endocrinology, Academic Hospital, Brussels Free University - VUB, Brussels, Belgium
    Drugs R D 7:99-110. 2006
    ..CONCLUSIONS: The observed effects of MK-0767 on adiponectin, free fatty acids and lipids, even after single doses, demonstrate that this prototypical dual PPAR alpha/gamma agonist has clinically meaningful activity in vivo...
  21. ncbi Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood
    Ilse Weets
    Diabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
    J Clin Endocrinol Metab 87:2597-605. 2002
    ..The overrepresentation of these susceptibility genotypes in antibody-negative patients suggests the existence of an immune-mediated disease process with as yet unidentified immune markers in a subgroup of seronegative patients...
  22. ncbi The incidence of type 1 diabetes in the age group 0-39 years has not increased in Antwerp (Belgium) between 1989 and 2000: evidence for earlier disease manifestation
    Ilse Weets
    Diabetes Research Center, Free University, Brussels, Belgium
    Diabetes Care 25:840-6. 2002
    ..The results suggest that an environmental factor may preferentially accelerate the subclinical disease process in young diabetes-prone subjects...
  23. ncbi Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  24. ncbi Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation
    Volkert A L Huurman
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    PLoS ONE 3:e2435. 2008
    ..We tested the hypothesis that allograft rejection and recurrent autoimmunity contribute to this progressive loss of islet allograft function...
  25. ncbi Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial
    M Davies
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Diabetes Obes Metab 10:387-99. 2008
    ..This subgroup analysis investigated the initiation of once-daily glargine therapy in patients suboptimally controlled on multiple OADs...
  26. ncbi Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft
    Bart Keymeulen
    Diabetes Research Center and Academisch Ziekenhuis, Vrije Universiteit Brussel, B-1090 Brussels, Belgium
    Proc Natl Acad Sci U S A 103:17444-9. 2006
    ..Thus, 1-year metabolic control can be reproducibly achieved and standardized by cultured islet cell grafts with defined beta cell number...
  27. ncbi Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients
    Corine A van Kampen
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
    Transplantation 80:118-26. 2005
    ..They demonstrate the usefulness of monitoring T-cell reactivity against islet allografts to correlate immune function with graft survival and to identify conditions for preservation of beta-cell function...
  28. ncbi Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
  29. ncbi Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
    ..The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated...
  30. ncbi Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts
    Geert Maleux
    Department of Radiology, University Hospitals Gasthuisberg, Leuven, Belgium
    J Vasc Interv Radiol 16:1693-7. 2005
    ..To evaluate the safety, feasibility, and clinical efficacy of percutaneous transhepatic injection of beta-cell grafts in patients with type 1 diabetes mellitus...
  31. ncbi Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes
    Gabrielle G M Pinkse
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands
    Proc Natl Acad Sci U S A 102:18425-30. 2005
    ..We demonstrate that CD8 T cell autoreactivity is associated with beta cell destruction in type 1 diabetes in humans...